Regardless, our data provide “a warning” for the use of DNA demethylating agent as an anti-cancer therapy, and provide proof reinforcing the necessity to use specific DNMT inhibitors or unspecific DNMT1 inhibitors with an adequate and optimized dose-schedule such as already described by several publications11, 12, 13. The gene discussed is DNMT1; the disease is cancer.